What Is SLC6A14? Its Role in Cellular Function and Cancer

SLC6A14 is a protein that acts as a gateway on the surface of cells, pulling amino acids from the surrounding environment into the cell interior. What makes it unusual is its appetite: it can transport 18 of the 20 standard amino acids, including every essential amino acid your body cannot make on its own.¹ That breadth of function is rare among amino acid transporters and is precisely what has drawn cancer researchers’ attention, because fast-growing tumors are hungry for amino acids and tend to hijack SLC6A14 to feed themselves.

What SLC6A14 Actually Does

Cells need amino acids the way a construction crew needs raw materials. Amino acids build proteins, fuel energy production, and feed the signaling networks that tell a cell when to grow or divide. SLC6A14 (sometimes called ATB^0,+ in older literature) sits in the cell membrane and imports amino acids using the energy stored in the concentration gradients of sodium and chloride ions. The only amino acids it does not handle are the two acidic ones, aspartate and glutamate.² Everything else, whether the amino acid carries a positive charge, a negative charge, or no charge at all, can ride through this one transporter.

Recent electrophysiology work has shown that SLC6A14 adjusts how many sodium ions it couples to each amino acid depending on the charge of the amino acid being transported. For a neutral amino acid like glycine, the ratio is roughly three sodium ions per amino acid molecule, but the coupling shifts when the transporter handles a positively charged amino acid instead.³ That variable coupling is part of how SLC6A14 maintains its ability to concentrate amino acids inside the cell even against steep gradients, something that matters a great deal in the context of tumor growth.

Where SLC6A14 Is Found in Healthy Tissue

In a healthy body, SLC6A14 is not expressed everywhere. It appears mainly in epithelial cells, the sheet-like cells that line surfaces such as the airways and the digestive tract. Lung epithelium carries the highest expression, with somewhat lower levels in the gastrointestinal lining.⁴ In the airways, one of its key jobs is transporting the amino acid L-arginine out of the thin layer of liquid that coats the bronchial surface.⁵ That detail turns out to be medically important for reasons beyond cancer, as we will see when we get to cystic fibrosis.

The relatively restricted expression in normal tissue is part of what makes SLC6A14 interesting as a therapeutic target. Many other amino acid transporters are expressed broadly across the body, which means blocking them would cause widespread side effects. SLC6A14’s narrower footprint in healthy organs suggests that interfering with it might be more selective.

Why Cancer Cells Upregulate SLC6A14

Tumors grow fast, and fast growth demands a constant supply of building blocks. Cancer cells often solve this problem by cranking up the production of nutrient transporters, and SLC6A14 is a particularly attractive one to exploit because it imports nearly every amino acid a cell could want. Researchers have found SLC6A14 significantly overexpressed in several aggressive solid tumors, including colorectal cancer, estrogen-receptor-positive breast cancer, cervical cancer, and pancreatic ductal adenocarcinoma.⁶

The upregulation is not a minor tweak. In pancreatic cancer, SLC6A14 expression was elevated several-fold in patient-derived tumors and cancer cell lines compared with normal pancreatic tissue, and it showed the largest increase of any amino acid transporter examined.⁷ That degree of overexpression suggests the tumor is not just passively benefiting from a transporter that happens to be around; it is actively ramping up production to sustain its metabolic needs.

Cancer-Specific Findings Across Tumor Types

Pancreatic Cancer

Pancreatic ductal adenocarcinoma is one of the most nutrient-starved tumor environments in the body, because the tumors are surrounded by dense connective tissue that restricts blood supply. SLC6A14’s ability to concentrate amino acids becomes especially valuable in that setting. Analysis of nearly 180 human pancreatic tumors versus a comparable number of normal pancreas samples showed significant overexpression of SLC6A14 in the tumors. There was also a reciprocal relationship between expression level and survival: higher SLC6A14 expression correlated with lower survival probability.⁶ A machine-learning study confirmed that SLC6A14 expression was an independent prognostic factor for both overall survival and disease-specific survival in pancreatic cancer patients.⁸

Colorectal Cancer

Colorectal cancer is the context where the connection between SLC6A14 and the Wnt signaling pathway has been most clearly mapped. In normal colon cells, the Wnt pathway controls growth and self-renewal. In most colon cancers, Wnt signaling is abnormally activated, and researchers found that SLC6A14 is a direct transcriptional target of this pathway. When they blocked Wnt signaling in colon cancer cells that had high SLC6A14 expression, transporter levels dropped. When they activated the pathway in cells with low baseline expression, transporter levels rose.⁹ Separately, SLC6A14 has been shown to promote both proliferation and metastasis of colorectal cancer cells via the JAK2/STAT3 signaling axis, pointing to multiple downstream consequences of its overexpression.¹⁰

Breast Cancer

In breast cancer, SLC6A14 upregulation is specifically tied to estrogen-receptor-positive tumors. Studies using both primary human breast cancer tissue and cell lines showed that SLC6A14 is an estrogen/ER target, meaning estrogen signaling directly drives its expression.¹¹ This subtype specificity is a clue for potential therapeutic strategies: targeting SLC6A14 would be most relevant in ER-positive breast cancers, which are the most common subtype.

Lung Cancer

The relationship between SLC6A14 and lung cancer is more complex and does not follow the simple “higher expression equals worse prognosis” pattern seen in some other tumor types. A study of lung cancer patients found that SLC6A14 was actually downregulated in both lung adenocarcinoma and lung squamous cell carcinoma compared with adjacent normal tissue. Paradoxically, lower expression of SLC6A14 at diagnosis correlated with shorter five-year overall survival.¹² The reasons for this inverted pattern are not fully understood, though it may relate to the fact that normal lung tissue already has high SLC6A14 expression, so changes in lung tumors could reflect different biology than what happens in organs where the transporter is normally low.

How SLC6A14 Feeds Cancer Growth Pathways

Importing amino acids is only the first step. Once those amino acids accumulate inside the cell, they trigger growth-promoting signaling cascades. The best-studied connection is to the mTOR pathway, a central regulator of cell growth that responds to nutrient availability. In colorectal cancer cells, SLC6A14 was shown to regulate the expression and activation of the Akt-mTOR signaling chain. When researchers blocked SLC6A14 using a pharmacological inhibitor, mTOR signaling was suppressed.¹³

A similar mechanism plays out in gastric cancer. When SLC6A14 was depleted or pharmacologically blocked in gastric cancer cells, the resulting amino acid starvation dampened the PI3K/AKT/mTOR pathway and suppressed a process called epithelial-mesenchymal transition, which is how cancer cells acquire the ability to migrate and metastasize.¹⁴ The pattern is consistent: cut off the amino acid supply through SLC6A14, and you starve the signaling networks that drive tumor growth and spread.

Blocking the Transporter With Alpha-Methyltryptophan

The most extensively studied pharmacological tool against SLC6A14 is alpha-methyltryptophan (α-MT), a modified form of the amino acid tryptophan. Unlike natural tryptophan, which would simply be imported by the transporter, α-MT jams the transporter without being carried through. It sits in the binding site and blocks it, preventing real amino acids from entering. Under conditions that simulate normal blood amino acid levels, α-MT blocks SLC6A14 with an IC₅₀ of roughly 250 micromolar.¹⁵

In laboratory experiments, treating cancer cells that express SLC6A14 with α-MT suppressed their ability to form colonies and triggered cell-cycle arrest, meaning the cells stopped dividing. Cells that did not express SLC6A14 were unaffected by the same treatment, which is exactly the kind of selectivity you want in a cancer drug.¹⁵ In pancreatic cancer models, α-MT induced amino acid starvation and reduced tumor growth both in cell cultures and in mice.⁷

One challenge researchers have identified is that cancer cells can find workarounds. Pancreatic cancer cells, for instance, can use autophagy (recycling their own internal components) or macropinocytosis (engulfing extracellular fluid to harvest dissolved nutrients) to compensate when SLC6A14 is blocked. A recent study found that combining SLC6A14 blockade with inhibition of these alternative nutrient-scavenging pathways enhanced the therapeutic effect in pancreatic cancer models.⁶ That kind of combination strategy may ultimately be necessary for a nutrient-deprivation approach to work in practice.

A Two-Way Therapeutic Idea

Beyond simply blocking SLC6A14 to starve tumors, researchers have proposed using the transporter’s broad appetite as a drug-delivery channel. The concept is straightforward: attach an anticancer drug to an amino acid, creating a prodrug that SLC6A14 recognizes as a normal substrate and imports. Because SLC6A14 is overexpressed on tumor cells but present at low levels in most normal tissues, the drug would preferentially accumulate in the tumor. This dual-use strategy, using SLC6A14 both as a target for inhibition and as a shuttle for delivering therapeutics, is still in its early stages but represents a creative angle on transporter biology.¹⁶

What Turns SLC6A14 On in Cancer Cells

Understanding what drives SLC6A14 overexpression is as important as understanding what the transporter does once it is active. Multiple transcriptional pathways have been implicated. In colon cancer, as already discussed, the Wnt/β-catenin pathway directly activates the SLC6A14 gene. Researchers identified four consensus binding sites for the TCF4/β-catenin complex in the SLC6A14 promoter region, and chromatin immunoprecipitation confirmed that this complex physically binds to the promoter.⁹

In ER-positive breast cancer, estrogen signaling is the driver.¹¹ A transcription factor called SP1 has been shown to bind the SLC6A14 promoter and upregulate its expression as well, a mechanism demonstrated in the context of ulcerative colitis research.¹⁷ There is also a genetic regulatory dimension: a specific single-nucleotide variant (rs4446858) within an enhancer element of the SLC6A14 gene alters the binding site for the transcription factor IRF1, and the alternate allele at this position increases SLC6A14 expression in response to interferon-gamma stimulation.¹⁸ The fact that so many different pathways converge on SLC6A14 helps explain why it gets activated across such varied cancer types.

SLC6A14 and Cystic Fibrosis

Cancer is not the only disease context where SLC6A14 matters. Because the transporter is expressed in airway epithelium and handles L-arginine, it intersects with cystic fibrosis lung disease in a meaningful way. L-arginine in the airway surface liquid is used by the body to produce nitric oxide, an antimicrobial molecule. It also feeds the bacterium Pseudomonas aeruginosa, which is one of the most dangerous infections for people with CF. SLC6A14 transports arginine out of the airway surface liquid and into the epithelial cells, which reduces the arginine available to bacteria on the airway surface.⁵

Genetic variation in SLC6A14 has been identified as a modifier of CF severity. A genome-wide association meta-analysis found that variants near SLC6A14 on the X chromosome were significantly associated with lung disease severity in people with CF, with effect sizes translating to measurable changes in lung function.¹⁹ A follow-up study confirmed that a specific variant (rs3788766) in SLC6A14 was associated with lung disease severity in over 3,200 pancreatic-insufficient CF patients, with the minor allele linked to worse outcomes. That study also connected SLC6A14 to mTOR signaling and epithelial repair, suggesting the same growth-related pathways exploited by cancer cells may play a role in how the airway responds to chronic CF inflammation.²⁰

The X-chromosome location of SLC6A14 is worth noting here. Because males carry only one X chromosome, they have only one copy of the gene, which means a single detrimental variant has no backup copy to compensate. Females, with two X chromosomes, may have a buffering copy, though X-inactivation complicates the picture. This chromosomal quirk may partly explain sex differences observed in CF lung disease progression, and it also came up in the lung cancer study, where SLC6A14 expression differed by sex in squamous cell carcinoma patients.¹²

How Far Along Are Clinical Applications

As of now, no drug specifically targeting SLC6A14 has entered clinical trials. The work described above, including the α-MT experiments and the combination strategies in pancreatic cancer, remains preclinical, meaning it has been tested in cell cultures and animal models but not yet in human patients. That said, the evidence base is growing in a direction that makes clinical translation plausible. The transporter is overexpressed in multiple common cancers, its blockade has consistent anti-tumor effects in lab models, its expression in normal tissue is limited enough to suggest a reasonable therapeutic window, and its expression level correlates with patient survival in at least pancreatic cancer.

The prodrug delivery concept adds another dimension that pharma researchers find appealing, because it could potentially repurpose existing anticancer drugs by coupling them to amino acid carriers that SLC6A14 would recognize.¹⁶ The challenge will be the same one that faces most novel cancer targets: proving in humans that blocking or exploiting the transporter has meaningful effects on tumor growth without unacceptable toxicity. The preclinical evidence is promising, but the gap between a mouse model and a clinical trial remains wide.

For people following cancer biology, SLC6A14 sits in a broader trend of targeting tumor metabolism rather than just targeting oncogenes or immune checkpoints. The logic is appealing in its simplicity: if you can cut off a tumor’s food supply through a channel the tumor has become dependent on, you create a vulnerability that normal cells, which have alternatives and lower demand, can survive. Whether that logic holds up in the clinic is the open question that the next few years of research will need to answer.